Workforce Development & Leadership

Fluid Biomed Appoints John Kilcoyne as Independent Board Chair

Appointment expands the company’s leadership expertise as Fluid Biomed advances development of its polymer-based stent technology to treat brain aneurysms and stroke.

Fluid Biomed Inc. (“Fluid Biomed”), a medical device company dedicated to advancing neurovascular innovation, today announced the appointment of John Kilcoyne as Independent Chair of its Board of Directors. Mr. Kilcoyne’s appointment broadens the company’s sector expertise as it accelerates development of its unique polymer-based stent technology to treat brain aneurysms and stroke.

Mr. Kilcoyne has led a distinguished 40-plus-year career in the medical device industry at both Board and Executive levels. Over this period, he has demonstrated exceptional leadership, built success-oriented cultures, and guided multiple organizations through reorganizations, acquisitions, startups, and public offerings. His leadership has generated more than $1 billion in value through a combination of initial public offerings and acquisitions.

“We are thrilled to welcome John Kilcoyne as Independent Chair of our Board,” said Dr. John Wong, co-founder and Chief Executive Officer of Fluid Biomed. “His strategic insight and leadership strength will significantly enhance our Board’s guidance as we aim to secure our next milestones.”

“John’s decades of experience in leading high-growth medical device companies, navigating complex regulatory pathways, and executing successful IPOs and acquisitions will be invaluable as we scale toward commercialization,” said Dr. Alim Mitha, Fluid Biomed co-founder, President, and Chief Technology Officer.

“I am honored to join Fluid Biomed at such a pivotal moment,” said Mr. Kilcoyne. “I share the company’s vision for transforming brain aneurysm and stroke therapy and enabling physicians with their compelling technology to better serve patients worldwide. I look forward to working closely with the Board and executive team to support strategic growth, accelerate clinical progress, and deliver meaningful impact for patients and stakeholders.”

Related posts

Libris Innovations Appoints Ramani Varanasi as CEO

PR Newswire

Efekta Launches English Training for Teachers and Students in Africa

PR Newswire

Assembly Health Expands Revenue Cycle Management Team

PR Newswire